Vertex Appoints Charles Wagner as Chief Financial Officer

About this update from Vertex Pharmaceuticals Incorporated

[{"type":"text","content":"BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019. Mr. Wagner will report directly to Vertex Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D., and oversee the finance, internal audit, investor relations, and global security and facilities functions. Mr. Wagner joins Vertex with deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.\"Charlie is a proven finance leader with extensive experience working in a public company setting, and he will be a tremendous asset to Vertex and our strong team,\" said Dr. Leiden. \"As we continue to build Vertex for the future, Charlie's strategic mindset, operational expertise, and broad leadership experience will prove invaluable. I'd like to thank our interim CFO, Paul Silva, for his contributions and leadership. Paul will continue in his role as Corporate Controller upon Charlie's arrival.\"Mr. Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. - a Carlyle Group portfolio company, where he served as CFO and EVP, Finance. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprise-wide projects. Prior to this, Mr. Wagner served as CFO for publicly- traded Bruker Corporation, Progress Software Corporation and Millipore Corporation. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand. He received his BS in accounting from Boston College and his MBA from Harvard Business School.\"I am excited to be joining Vertex at such a dynamic time as the company continues to deliver more transformational medicines for cystic fibrosis patients and accelerates its pipeline of innovative and novel life-changing treatments for patients with other serious diseases,\" said Mr. Wagner. \"I look forward to working with Vertex's senior leadership team and employees to help the company continue to drive value through its remarkable innovation.\"About VertexVertex is a global biotechnology company that invests ...

More updates from Vertex Pharmaceuticals Incorporated